Notice Regarding the Start of the SAKIGAKE Consultation for a Subsidiary’s AI-powered Cognitive Function Diagnostic Support App (SaMD)
Filed with TSE · · 2 pages · English
Summary by 6ix AI
This consultation aims to streamline the marketing approval process by obtaining prior evaluations from the Pharmaceuticals and Medical Devices Agency (PMDA). The filing indicates that the impact on consolidated financial results for the current fiscal year is minor, with no revisions to earnings forecasts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from ExaWizards
- Consolidated Financial Results for the Three Months Ended June 30, 2026
- Notice of Establishment of a New Company, ExaSecuriy Inc
- Notice Regarding Completion of Payment for Disposition of Treasury Shares as Restricted Stock Compensation
- Notice Regarding Disposition of Treasury Shares as Restricted Stock Compensation
- Notice of Establishment of a New Company, ExaForward Kyushu Inc.
Later from ExaWizards
- Notice Regarding the Acquisition of Shares of ele&company Inc
- Notice Regarding Changes in Major Shareholder and the Largest Major Shareholder
- Consolidated Financial Results for the Six Months Ended September 30, 2026
- Financial Results for the Second Quarter of FY2027/03
Follow ExaWizards into a list and get an email when it puts out news.
Follow ExaWizards